Preclinical studies have shown the successful application of MG1 as (1) a monotherapy,6 (2) a cancer vaccine vector expressing either tumor-associated or viral antigens,7, 9 (3) in combination with standard of care chemotherapeutic agents10 and (4) in combination with ICI in a neoadjuvant setting.11 Here, MUC5B is linked to neoplasm.